Geneseeq Achieves NMPA Approval for Innovative Diagnostic Kit
Geneseeq Technology Inc., a leading global precision oncology company, has reached a significant milestone with the recent approval of its PanTRKare™ NTRK1/NTRK2/NTRK3 Gene Fusion Detection Kit. The National Medical Products Administration (NMPA) of China has officially authorized this test as a groundbreaking companion diagnostic (CDx) for Roche's ROZLYTREK®. This momentous achievement makes PanTRKare™ the first next-generation sequencing (NGS)-based pan-solid tumor diagnostic kit approved in China, specifically designed to detect NTRK1, NTRK2, and NTRK3 gene fusions.
Understanding the Impact of NTRK Gene Fusions
NTRK gene family fusions are rare, occurring in less than 1% of all solid tumors, but they are known to be one of the most actionable mutations across various cancer types. Patients who possess these fusions can significantly benefit from targeted therapies like TRK inhibitors, including ROZLYTREK®. The advent of PanTRKare™ allows for precise and sensitive detection of these gene fusions, bringing hope to patients who have this uncommon yet crucial mutation.
Clinical Validation: A Robust Foundation
The validation of the PanTRKare™ kit comes from a comprehensive large-scale multi-center clinical study involving seven prominent hospitals, encompassing 33 tumor types and over 2,400 clinical samples. The assay has demonstrated exceptional accuracy, sensitivity, and reproducibility, successfully identifying more than 200 unique NTRK fusion variants. This extensive validation establishes PanTRKare™ as one of the most reliable NTRK companion diagnostics globally, ensuring its usefulness in both standard oncology and translational research settings.
Charting New Paths in Targeted Therapies
Clinical bridging studies conducted with ROZLYTREK® revealed a high level of agreement in testing results, along with comparable objective response rates among patients who test positive for NTRK fusions. This result illustrates the clinical relevance of the PanTRKare™ test and its critical role in promoting advancements in precision medicine to benefit patients with these unique genetic changes.
Commitment to Advancing Oncology Diagnostics
Dr. Yang Shao, the CEO of Nanjing Geneseeq Technology Inc., expressed enthusiasm about the approval of PanTRKare™, stating, "With the NMPA approval, clinicians across China can now access a reliable tool to identify patients with NTRK gene fusions, connecting them to effective targeted therapies. This approval signifies Geneseeq's unwavering commitment to enhancing precision oncology and improving patient outcomes through innovative molecular diagnostics." Dr. Shao also emphasized Geneseeq's future plans to drive innovation in oncology diagnostics through global regulatory collaborations, biopharma partnerships, and a focus on patient-centered products.
About Geneseeq Technology Inc.
Geneseeq Technology Inc. is a research-intensive leader in the field of precision oncology, focusing on advanced next-generation sequencing (NGS) methodologies to revolutionize cancer detection, diagnosis, and treatment modalities. The company’s extensive portfolio includes detailed genomic profiling across various tumor types, alongside cancer-specific diagnostic panels, minimal residual disease (MRD) monitoring, and multi-cancer early detection (MCED) solutions.
The flagship product of Geneseeq, the GeneseeqPrime® tumor profiling assay, is now FDA-cleared, CE-IVD marked, and NMPA-approved, ensuring its accessibility in key markets globally. Additionally, four other Geneseeq diagnostic panels have secured CE-IVD marking, and the CanScan® MCED assay has received the FDA Breakthrough Device Designation.
With its headquarters in both Canada and China, Geneseeq operates laboratories that are accredited by CAP and CLIA, partnering with hospitals, academic institutions, and pharmaceutical entities worldwide to accelerate precision medicine and enhance biomarker-driven therapeutic developments.
Frequently Asked Questions
What is the significance of the NMPA approval for Geneseeq?
The NMPA approval of the PanTRKare™ diagnostic kit marks a milestone in China, allowing for advanced detection of NTRK gene fusions in solid tumors.
How does PanTRKare™ contribute to cancer treatment?
PanTRKare™ enables accurate detection of rare NTRK gene fusions, facilitating patient access to targeted therapies such as ROZLYTREK®.
What was the scope of the clinical validation for the kit?
The kit underwent extensive validation through a study involving seven hospitals, 33 tumor types, and over 2,400 clinical samples, proving its accuracy and reliability.
What are the future plans for Geneseeq Technology Inc.?
Geneseeq aims to continue driving innovation in oncology diagnostics through collaborations and developing patient-focused products.
What is Geneseeq's contribution to precision oncology?
Geneseeq is dedicated to transforming cancer detection and treatment through advanced NGS technologies and comprehensive genomic profiling.
